The Executive Who Just Sold His TRIB1 Report For A Billion Dollars

1 defined daily doses (DDD) per month (p?Akt inhibitor trend, with the number of cases decreasing by 3% per month [multiplicative factor of exp(?0.032)?=?0.97 per month (p?0.04, 95% CI 0.94�C1.00)]. After the intervention, there was a significant change, with the number of cases decreasing by 8% per month (multiplicative decrease per month was exp(?0.032)?��?exp(?0.047)?=?0.92 (p?0.03, 95% CI 0.86�C0.99). The goodness of fit of the model was adequate (��2?=?31.5, p?0.11). The proportion of TRIB1 CDI cases each month with an onset in the community varied between 0.29 and 0.73. There was no significant change in the proportion of Ibrutinib supplier community cases before and after the intervention. C.?difficile was cultured from 68 and 59 cases in phases 1 and 2 of the study, respectively. The proportion of cases caused by different REA types is shown in Table?3. Ribotypes are inferred from Killgore et?al. [11]. In both phases, REA type/ribotype strains DH/106 and BI/027 predominated. There was no significant difference in the frequency of different strain types between the study phases (p?0.17). We have reported the impact of an initiative to combat CDI that was associated with a sustained reduction in the number of CDI cases at our hospital. We have described the intervention and analysis in line with the ORION statement on reporting intervention studies in nosocomial infection [12]. We have chosen to analyse the impact of the intervention on the total number of CDI cases per month rather than correcting for number of admissions or bed occupancy because our CDI patients are almost exclusively very elderly and have extensive health care contact, even if their CDI symptoms had an onset outside hospital. Consequently, it does not appear to be appropriate to either exclude the community-onset cases from analysis or to correct the total case number for our hospital activity. Nevertheless, because the burden of CDI is more commonly presented as rate per 10000 bed days for hospital-onset disease, we also provide these data in Fig.?1.